Meritxell Bellet-Ezquerra

12PUBLICATIONS
149CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEnvironmental epidemiologyPredictive and prognostic markersMineral processing/beneficiation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 10, 2026
Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

|Apr 24, 2026
Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?

|Dec 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.

Barbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro

|Jan 17, 2025
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.

Maria Vidal, Claudette Falato, Tomás Pascual

|May 01, 2024
Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance.

Arnau Llinas-Bertran, Meritxell Bellet-Ezquerra, Jose A Seoane

|Apr 01, 2024
First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN.

N Martínez-Jañez, M Bellet Ezquerra, L M Manso Sanchez

Pageof 2

Frequent Collaborators

4 joint publications

Begoña Bermejo

2 joint publications

Heather M Moore

2 joint publications

Cristina Saura

2 joint publications

Ana Santaballa Bertran